Product

Recombinant influenza vaccine

Aliases

Recombinant influenza vaccine (RIV4), Supemtek / Flublok Quadrivalent

1 clinical trial

1 indication

Indication

Influenza Immunization

Clinical trial

Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine Compared With Egg-Based Standard-Dose Quadrivalent Influenza Vaccine in Children 3 to 8 Years of Age.

Status: Terminated, Estimated PCD: 2023-10-03